Various shapes in red, orange, yellow, blue, and teal on a dark purple background.

CSUA Level 2 Seed Grant

- Closed -

Addressing Issues Of Substance Use And Addiction
Eligibility: Faculty at University Park and Commonwealth Campuses
Financial support range: $5,000-$20,000
Deadline: Proposals are due on March 15, 2023

Priority will be given to projects that make a convincing case for how the developing research program can advance solutions to the systemic problems of substance use and addiction. 

Learn More on CSUA Website

Funded Projects

Project Team
Louisa Holmes, Assistant Professor, Geography / Demography

Project Description

More than 564,000 people in the US have died from an opioid overdose in the past 20 years. Most people in the US facing opioid use disorder (OUD) were first introduced to opioids via a physician’s prescription, with drugs marketed to them by the pharmaceutical industry. Lawsuits against companies like Purdue Pharma have demonstrated that the pharmaceutical industry aggressively promoted opioid prescriptions, knowing that they were addictive. As a result of these lawsuits, millions of pages of corporate documents have been released, indexed, and made publicly available via the UCSF-Johns Hopkins University Opioid Industry Documents Archive (OIDA).1 As of March 2023, the OIDA housed 11,635,283 pages of corporate documentation, with millions more pages scheduled to be released shortly. We propose to develop a search and analysis methodology using the OIDA, focusing on Purdue Pharma and its management consultant firm, McKinsey & Company (~78,000 total documents), as a demonstration study to systematically search and analyze the documents for industry interference in the implementation of state opioid laws, including prescription drug management programs (PDMPs), pain management clinic regulation, and prescription duration policies.

Project Team
Tanzil Arefin, Assistant Research Professor, Biomedical Engineering

Project Description

Alcohol use disorder (AUD) is a chronic relapsing disorder, characterized by excessive alcohol drinking and loss of control over consumption, and has dramatic consequences for individuals’ health and productivity, their families, and society. Emerging studies suggest that at the neurobiological level, alcohol acts as a complex drug that modifies the activity of multiple molecular targets and triggers broad alterations of gene expression and synaptic plasticity. Excessive alcohol consumption is therefore associated with significant changes in brain morphology including degradation in white matter (WM) integrity that carries information between gray matter (GM) regions and modifying the neural networks responsible for reward, mood, and decision making. There is some evidence that women are more susceptible to alcohol induced brain changes, however the data remains inconclusive. By using an animal model, we can systematically examine the consequences of chronic alcohol exposure in male and female rodents. Specifically, we can evaluate structural, and neuro-architecture changed by chronic alcohol exposure. Over the past decades, tremendous efforts have been made in mapping neural architecture at various scales, such as delineating white matter tracts by mesoscopic tracing of axonal projections, to the identification of cellular-level connections and the synaptic molecular properties. However, this technique relies on the assessment of a single brain, and thus quantitative assessment of neuronal reorganization in multiple sexes or between drug treatments remains a challenge. Hence, the broad goal of this study is to establish a framework to understand the causative link between chronic alcohol exposure and resulting brain structural connectome specific to sex by cross-examination of male and female C57BL/6J mice using high-resolution diffusion MRI (dMRI). The outcome of our proposed study will therefore stand out as a prevailing workbench for neuroscientists to study sex differences in the development of AUD and further supportive to the advancement of new pivotal therapeutic concepts.